Fall Skin Care Sale

Erectile Dysfunction References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Heidelbaugh JJ. Management of erectile dysfunction. Am Fam Physician. 2010;81(3):305-312.
  2. McVary KT. Clinical practice.Erectile dysfunction.The New England journal of medicine. Dec 13 2007;357(24):2472-2481.
  3. Berookhim BM, Bar-Chama N. Medical implications of erectile dysfunction. Med Clin North Am. 2011;95(1):213-221.
  4. Cellerino A, Jannini EA. Why humans need type 5 phosphodiesterase inhibitors. Int J Androl. 2005;2:14-17.
  5. Sadeghi-Nejad H, Brison D, Dogra V. Male Erectile Dysfunction. Ultrasound Clinics. 2007;2(1):57-71.
  6. Kolodny L. (2011) Chapter 17: Men’s Health: Erectile Dysfunction (pg. 971). In: Bope E., Kellerman R. (Eds.), Conn's Current Therapy (1st ed). Saunders, An Imprint of Elsevier.
  7. Segal R, Burnett AL. Avanafil for the treatment of erectile dysfunction.Drugs Today. 2012;48(1):7-15.
  8. Stroberg P, Hedelin H, Bergstrom A. [Sex--only for the rich and healthy?PDE5 inhibitors too expensive for low income men].Lakartidningen. 2006;103(39):2865-2867.
  9. Rashid A. The efficacy and safety of PDE5 inhibitors.Clinical Cornerstone. 2005;7(1):47-55.
  10. Burnett A. (2011) Chapter 24: Evaluation and Management of Erectile Dysfunction (pg 721). In: Wein A. (Ed.), Campbell-Walsh Urology (10th ed). Saunders, An Imprint of Elsevier.
  11. Wolfe SM. There have been inadequate warnings that erectile dysfunction drugs can cause blindness: MedGenMed. 2005 Dec 5;7(4):61.
  12. Gandaglia G, Salonia A, Passoni N, Montorsi P, Briganti A, Montorsi F. Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. Endocrine. Sep 5 2012.
  13. Garcia-Cruz E, Piqueras M, Gosalbez D, Perez-Marquez M, Peri L, Izquierdo L, . . . Alcaraz A. [Erectile dysfunction and its severity are related to the number of cardiovascular risk factors]. Actasurologicasespanolas. May 2012;36(5):291-295.
  14. Ewane KA, Lin HC, Wang R. Should patients with erectile dysfunction be evaluated for cardiovascular disease? Asian J Androl. 2012;14(1):138-144.
  15. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Archives of internal medicine. Nov 14 2011;171(20):1797-1803.
  16. AUA (American Urological Association) Managing Your Peyronie’s Disease. In: Ferri’s Netter Patient Advisor (pg. 988) Copyright 2012 Saunders, an imprint of Elsevier, Inc.
  17. NIH (National Institutes of Health) Impotence.NIH Consens Statement. 1992;10(4):1-33.
  18. Ritchie R, Sullivan M. Endothelins& erectile dysfunction. Pharmacol Res. 2011;63(6):496-501.
  19. Paroni R, Barassi A, Ciociola F, et al. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and L-arginine in patients with arteriogenic and non-arteriogenic erectile dysfunction. Int J Androl. 2012;20(10):1365-2605.
  20. Ginsberg TB. Male sexuality.ClinGeriatr Med. 2010;26(2):185-195.
  21. Morales A. Androgens are fundamental in the maintenance of male sexual health. CurrUrol Rep. 2011;12(6):453-460.
  22. MacKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev. 2004;9(1):4-16.
  23. Fortney L. (2012) Chapter 60: Erectile Dysfunction (pg 560). In: Rakel D. (Ed.), Integrative Medicine (3rd ed). Saunders, An Imprint of Elsevier.
  24. Hackett G. The burden and extent of comorbid conditions in patients with erectile dysfunction.Int J ClinPract. 2009;63(8):1205-1213.
  25. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clin Proc. 2012;87(8):766-778.
  26. Hannan JL, Maio MT, Komolova M, Adams MA.Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med. 2009;3:254-261.
  27. Nunes KP, Labazi H, Webb RC. New insights into hypertension-associated erectile dysfunction.CurrOpinNephrolHypertens. 2012;21(2):163-170.
  28. Meldrum DR, Gambone JC, Morris MA, Meldrum DA, Esposito K, Ignarro LJ. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol. 2011;108(4):599-606.
  29. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3(1):28-36.
  30. Martin S, Atlantis E, Wilson D, et al. Clinical and Biopsychosocial Determinants of Sexual Dysfunction in Middle-Aged and Older Australian Men. J Sex Med. 2012;3(10):1743-6109.
  31. Hackett G. Testosterone measurement - mandatory in ALL men with ED. International Journal of Clinical Practice. 2012;66(1):113-113.
  32. Cattabiani C, Basaria S, Ceda GP, Luci M, Vignali A, Lauretani F, . . . Maggio M. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. Journal of endocrinological investigation. Jan 2012;35(1):104-120.
  33. Oloyo AK, Sofola OA, Nair RR, Harikrishnan VS, Fernandez AC. Testosterone relaxes abdominal aorta in male Sprague-Dawley rats by opening potassium (K(+)) channel and blockade of calcium (Ca(2+)) channel. Pathophysiology. 2011;18(3):247-253.
  34. Maggi M, Buvat J, Corona G, Guay A, Torres LO.Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA). J Sex Med. 2012;23(10):1743-6109.
  35. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. The Journal of urology. Jan 1994;151(1):54-61.
  36. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999;53(3):590-594.
  37. Reiter WJ, Schatzl G, Mark I, ZeinerA, Pycha A, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res. 2001;29(4):278-281.
  38. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol. 2007;52(1):54-70.
  39. Jankowska EA, Rozentryt P, Ponikowska B, Hartmann O, Kustrzycka-Kratochwil D, Reczuch K, . . . Ponikowski P. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA : the journal of the American Medical Association. May 13 2009;301(18):1892-1901.
  40. MD Consult. Phentolamine. Available at: http://www.mdconsult.com/das/pharm/body/371040816-2/0/full/481. Last updated 10/3/2009a. Accessed 10/8/2012.
  41. MD Consult. Papaverine. Available at: http://www.mdconsult.com/das/pharm/body/371041773-2/0/full/1495. 12/2/2009b. Accessed 10/8/2012.
  42. MD Consult. Alprostadil. Available at: http://www.mdconsult.com/das/pharm/body/371041791-4/0/full/1184?infotype=4 Revised 8/27/2010. Accessed 10/8/2012.
  43. Lea AP, Bryson HM, Balfour JA.Intracavernousalprostadil.A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.Drugs & aging. Jan 1996;8(1):56-74.
  44. Costabile RA, Mammen T, Hwang K.An overview and expert opinion on the use of alprostadil in the treatment of sexual dysfunction.Expert opinion on pharmacotherapy. Jun 2008;9(8):1421-1429.
  45. Rooney M, Pfister W, Mahoney M, Nelson M, Yeager J, Steidle C. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. The journal of sexual medicine. Feb 2009;6(2):520-534.
  46. MD Consult. Erectile Dysfunction. Available at: http://www.mdconsult.com/das/pdxmd/body/370348123-3/0?type=med&eid=9-u1.0-_1_mt_1014835 Updated: 2/10/2012a. Accessed 10/5/2012.
  47. Pinsky MR, Chawla A, Hellstrom WJ.Intracavernosal therapy and vacuum devices to treat erectile dysfunction.Archivosespanoles de urologia. Oct 2010;63(8):717-725.
  48. Melnik T, Soares BG, Nasello AG. The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. The journal of sexual medicine. Nov 2008;5(11):2562-2574.
  49. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. International journal of andrology. Apr 2012;35(2):190-195.
  50. MD Consult. Ferri: Ferri's Clinical Advisor 2013, 1st ed. Peyronie’s Disease. 2012b. Accessed 10/8/12. Available at: http://www.mdconsult.com/books/page.do?sid=1364882619&eid=4-u1.0-B978-0-323-08373-7..00025-X--sc0135&isbn=978-0-323-08373-7&uniqId=371041791-6
  51. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. The Journal of urology. May 2012;187(5):1769-1775.
  52. Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. The journal of sexual medicine. Jan 2012;9(1):259-264.
  53. Ledda A, Belcaro G, Cesarone MR, Dugall M, Schonlau F. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 2010;106(7):1030-3.
  54. La Vignera S, Condorelli R, Vicari E, D'Agata R, Calogero AE. Physical activity and erectile dysfunction in middle-aged men.J Androl. 2012;33(2):154-161.
  55. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18(4):405-410.
  56. Esposito K, Giugliano F, Maiorino MI, Giugliano D. Dietary factors, Mediterranean diet and erectile dysfunction. J Sex Med. 2010;7(7):2338-2345.
  57. Giugliano F, Maiorino MI, Bellastella G, et al. Adherence to Mediterranean diet and erectile dysfunction in men with type 2 diabetes. J Sex Med. 2010;7(5):1911-1917.
  58. Zhang Q, Radisavljevic ZM, Siroky MB, Azadzoi KM. Dietary antioxidants improve arteriogenic erectile dysfunction. Int J Androl. 2011;34(3):225-235.
  59. Ho CC, Tan HM. Rise of herbal and traditional medicine in erectile dysfunction management.CurrUrol Rep. 2011;12(6):470-478.
  60. Chung E, Brock GB. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.CurrUrol Rep. 2011;12(6):432-43.
  61. de Andrade E, de Mesquita AA, Claro Jde A, et al. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian J Androl. 2007;9(2):241-244.
  62. NIH (National institutes of Health) MESH Terms: Arginine. Accessed 8/6/12. Available at: http://www.ncbi.nlm.nih.gov/mesh/68001120
  63. Gentile V, Antonini G, AntonellaBertozzi M, et al. Effect of propionyl-L-carnitine, L-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes.Curr Med Res Opin. 2009;25(9):2223-8.
  64. Mathers MJ, Brandt AS, Rundstedt F, Roth S, Sommer F, Klotz T. [Metabolism of nitric oxide (NO) and arginine: significance for male health]. Aktuelle Urol. 2009;40(4):235-241.
  65. Masuda H. Significance of nitric oxide and its modulation mechanisms by endogenous nitric oxide synthase inhibitors and arginase in the micturition disorders and erectile dysfunction.Int J Urol. 2008;15(2):128-134.
  66. Nunes KP, Toque HA, Caldwell RB, Caldwell RW, Webb RC. Extracellular signal-regulated kinase (ERK) inhibition decreases arginase activity and improves corpora cavernosal relaxation in streptozotocin (STZ)-induced diabetic mice. J Sex Med. 2011;8(12):3335-44.
  67. Cormio L, De Siati M, Lorusso F, et al. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77(1):119-22.
  68. Aoki H, Nagao J, Ueda T, et al. Clinical assessment of a supplement of Pycnogenol(R) and L-arginine in Japanese patients with mild to moderate erectile dysfunction. Phytother Res. 2012;26(2):204-7.
  69. Giles TD. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J ClinHypertens. 2006;8(12 Suppl 4):2-16.
  70. Stanislavov R, Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Marital Ther. 2003;29(3):207-213.
  71. Stanislavov R, Nikolova V, Rohdewald P. Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial. Int J Impot Res. 2008;20(2):173-180.
  72. Stanislavov R, Nikolova V, Rohdewald P. Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother Res. 2009;23(3):297-302.
  73. EBDR (European Bulletin of Drug Research). 2005;13(1): 7–13.
  74. Nikolova V, Stanislavov R, Vatev I, Nalbanski B, Punevska M. [Sperm parameters in male idiopathic infertility after treatment with prelox]. AkushGinekol. 2007;46(5):7-12.
  75. Gianfrilli D, Lauretta R, Di Dato C, et al. Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. Andrologia. 2012;1:600-604.
  76. Porst H. The future of erectile dysfunction (ED). Arch Esp Urol. 2010;63(8):740-747.
  77. Ma H, He X, Yang Y, Li M, Hao D, Jia Z. The genus Epimedium: an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2011;134(3):519-541.
  78. Metz D, Weston P, Barker D. Case report of vasculitic rash induced by Ginkgo biloba and/or Horny Goat Weed. BMJ Case Rep. 2009;17:17.
  79. Shindel AW, Xin ZC, Lin G, et al. Erectogenic and neurotrophic effects of icariin, a purified extract of horny goat weed (Epimedium spp.) in vitro and in vivo. J Sex Med. 2010;7(4 Pt 1):1518-1528.
  80. Xin ZC, Kim EK, Lin CS, et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.Asian J Androl. 2003;5(1):15-18.
  81. Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL.Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats.Asian J Androl. 2005;7(4):381-388.
  82. Liu T, Xin H, Li WR, et al. Effects of icariin on improving erectile function in streptozotocin-induced diabetic rats. J Sex Med. 2011;8(10):2761-2772.
  83. Zhang J, Wang YB, Ma CG, et al. Icarisid II, a PDE5 inhibitor from Epimediumwanshanense, increases cellular cGMP by enhancing NOS in diabetic ED rats corpus cavernosum tissue. Andrologia. 2012;1:87-93.
  84. Tamler R, Mechanick JI. Dietary supplements and nutraceuticals in the management of andrologic disorders.EndocrinolMetabClin North Am. 2007;36(2):533-552.
  85. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res. 2000;12(1):S48-63.
  86. Kernohan AF, McIntyre M, Hughes DM, Tam SW, Worcel M, Reid JL. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J ClinPharmacol. 2005;59(1):85-93.
  87. Dinsmore WW. Available and future treatments for erectile dysfunction.Clin Cornerstone. 2005;7(1):37-45.
  88. Pushkar D, Segal AS, Bagaev AG, Nosovitskii PB.[Yohimbine in the treatment of erectile dysfunction].Urologiia. 2002;6:34-7.
  89. Tharyan P, Gopalakrishanan G. Erectile dysfunction. ClinEvid. 2006;15(51):1227-1251.
  90. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159(2):433-436.
  91. Morales A., Condra M, Owen JA, Surridge DH, Fenemore J, Harris C. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol. 1987;137(6):1168-1172.
  92. Tanweer MS, Fatima A, Rahimnajjad MK. Yohimbine can be the new promising therapy for erectile dysfunction in type 2 diabetics: J Pak Med Assoc. 2010 Nov;60(11):980.
  93. Ernst E, Posadzki P, Lee MS. Complementary and alternative medicine (CAM) for sexual dysfunction and erectile dysfunction in older men and women: an overview of systematic reviews. Maturitas. 2011;70(1):37-41.
  94. Shamloul R. Natural aphrodisiacs. J Sex Med. 2010;7(1 Pt 1):39-49.
  95. Nair R, Sellaturay S, Sriprasad S. The history of ginseng in the management of erectile dysfunction in ancient China (3500-2600 BCE). Indian J Urol. 2012;28(1):15-20.
  96. Chan SW. Panax ginseng, Rhodiolarosea and Schisandrachinensis.Int J Food SciNutr. 2012;1:75-81.
  97. Kim TH, Jeon SH, Hahn EJ, et al. Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction. Asian J Androl. 2009;11(3):356-361.
  98. Jang DJ, Lee MS, Shin BC, Lee YC, Ernst E. Red ginseng for treating erectile dysfunction: a systematic review. Br J ClinPharmacol. 2008;66(4):444-450.
  99. Wang X, Chu S, Qian T, Chen J, Zhang J. Ginsenoside Rg1 improves male copulatory behavior via nitric oxide/cyclic guanosine monophosphate pathway. J Sex Med. 2010;7(2 Pt 1):743-750.
  100. Zenico T, Cicero AFG, Valmorri L, Mercuriali M, Bercovich E. Subjective effects of Lepidiummeyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial. Andrologia. 2009;41(2):95-99.
  101. Hudson T. Maca: new insights on an ancient plant. Integrative Medicine: A Clinician’s Journal 2008;7(6):54-57.
  102. Shin BC, Lee MS, Yang EJ, Lim HS, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44.
  103. Zheng BL, He K, Kim CH, et al. Effect of a lipidic extract from lepidiummeyenii on sexual behavior in mice and rats.Urology. 2000;55(4):598-602.
  104. Gonzales GF, Cordova A, Vega K, et al. Effect of Lepidiummeyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia. 2002;34(6):367-372.
  105. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Mol Vis. 2012;18:390-402.
  106. Moyad MA. Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients? UrolClin North Am. 2002;29(1):11-22.
  107. Yeh KY, Pu HF, Kaphle K, et al. Ginkgo biloba extract enhances male copulatory behavior and reduces serum prolactin levels in rats. HormBehav. 2008;53(1):225-231.
  108. Rowland DL, Tai W. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. J Sex Marital Ther. 2003;29(3):185-205.
  109. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther. 1998;24(2):139-143.
  110. Kellis JT, Jr., Vickery LE.Inhibition of human estrogen synthetase (aromatase) by flavones.Science. Sep 7 1984;225(4666):1032-4.
  111. Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV. Disposition and metabolism of the flavonoid chrysin in normal volunteers.Br J ClinPharmacol. 2001 Feb;51(2):143-6.
  112. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food SciNutr. 2007;47(8):735-48.
  113. Malaguarnera M. Carnitine derivatives: clinical usefulness. CurrOpinGastroenterol. 2012;28(2):166-176.
  114. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63(4):641-646.
  115. Mingorance C, Rodriguez-Rodriguez R, Justo ML, Herrera MD, de Sotomayor MA. Pharmacological effects and clinical applications of propionyl-L-carnitine.Nutr Rev. 2011;69(5):279-290.
  116. Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin. 2004;20(9):1377-1384.
  117. Sorenson M, Grant WB. Does vitamin D deficiency contribute to erectile dysfunction? Dermatoendocrinol. 2012;4(2):128-136.
  118. Wang CH, Huang YF. [Hyperhomocysteinemia and erectile dysfunction: an update]. Zhonghua Nan KeXue. 2011;17(11):1019-1022.
  119. Lombardo F, Tsamatropoulos P, Piroli E, et al. Treatment of erectile dysfunction due to C677T mutation of the MTHFR gene with vitamin B6 and folic acid in patients non responders to PDE5i. J Sex Med. 2010;7(1 Pt 1):216-223.
  120. Khan MA, Thompson CS, Emsley AM, Mumtaz FH, Mikhailidis DP, Angelini GD, . . . Jeremy JY. The interaction of homocysteine and copper markedly inhibits the relaxation of rabbit corpus cavernosum: new risk factors for angiopathic erectile dysfunction? BJU international. Oct 1999;84(6):720-724.
  121. Ng CF, Lee CP, Ho AL, Lee VW.Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia. J Sex Med. 2011;8(10):2883-2893.
  122. Meldrum DR, Gambone JC, Morris MA, Esposito K, Giugliano D, Ignarro LJ. Lifestyle and metabolic approaches to maximizing erectile and vascular health.Int J Impot Res. 2012;24(2):61-68.
  123. Helmy MM, Senbel AM.Evaluation of vitamin E in the treatment of erectile dysfunction in aged rats. Life Sci. 2012;90(13-14):489-494.
  124. Kondoh N, Higuchi Y, Maruyama T, Nojima M, Yamamoto S, Shima H. Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: preliminary report. Aging Male. 2008;11(4):167-170.
  125. Ushiyama M, Kuramochi T, Yagi S, Katayama S. Antioxidant treatment with alpha-tocopherol improves erectile function in hypertensive rats. Hypertens Res. 2008;31(5):1007-1013.
  126. Balayssac S, Gilard V, Zedde C, Martino R, Malet-Martino M. Analysis of herbal dietary supplements for sexual performance enhancement: first characterization of propoxyphenyl-thiohydroxyhomosildenafil and identification of sildenafil, thiosildenafil, phentolamine and tetrahydropalmatine as adulterants. J Pharm Biomed Anal. 2012;63:135-150.
  127. Lee HM, Lee BJ. A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method. Food AdditContam Part AChem Anal Control Expo Risk Assess. 2011;28(4):396-407.
  128. Demizu Y, Wakana D, Kamakura H, Kurihara M, Okuda H, Goda Y. Identification of mutaprodenafil in a dietary supplement and its subsequent synthesis. Chem Pharm Bull. 2011;59(10):1314-1316.
  129. Petroczi A, Taylor G, Naughton DP. Mission impossible?Regulatory and enforcement issues to ensure safety of dietary supplements.Food ChemToxicol. 2011;49(2):393-402.
  130. Csupor D, Szekeres A, Kecskemeti A, et al. [Dietary supplements on the domestic market adulterated with sildenafil and tadalafil].OrvHetil. 2010;151(43):1783-1789.